

## VAP on fast growth trajectory

### *Overseas business resilient to global supply chain issues*

We met with Mr. Bharat Vageria, Co-founder, Managing Director, and CFO of Time Technoplast (TIME), to discuss the company's medium to long-term growth strategy across its Established Products and Value-added Products (VAP) segments. Below are the key takeaways from the discussion:

### VAP segment on a fast growth trajectory, led by composite CNG cascade cylinders

- Management remains confident of achieving over 20% revenue CAGR in the VAP segment (27% revenue mix in FY25), driven by composite CNG cascades (likely to clock a 30% CAGR).
- **In view of strong demand, healthy order book position, and optimal utilization of existing capacity, TIME is more than doubling its composite CNG cascade cylinder capacity to 1,080 cascades (commissioning likely soon) from 480 cascades currently.** Each cascade comprises 60 cylinders, each with a capacity of 156 liters (priced ~INR8m/cascade).
- **Following the expansion, TIME's revenue potential from composite CNG cascade cylinders is expected to exceed INR8b (FY25 revenue: ~INR4b), achievable over the next 2-3 years.**
- According to government guidelines and policies issued in Oct'20, the CNG cylinder market is estimated at INR280b across various products and applications.
- Currently, City Gas Distribution companies are in the process of setting up 8,181 CNG stations across 193 locations over the next eight years. This translates into ~INR22b annual revenue potential for Type-IV cylinders (metal & composite combined).
- TIME expects at least 30-40% conversion to Type-IV composite cylinders in the next few years and aims to capture the lion's share.
- With rising CNG demand in India, the expansion of its distribution network will necessitate a substantial increase in the number of CNG cascades.
- Additionally, the establishment of Compressed Biogas (CBG) plants by Reliance, Adani, and other giants is expected to further boost demand for CNG cylinders.
- Globally, the composite CNG cylinder market has evolved in phases—starting with cascades, followed by on-board products for commercial vehicles, then Passenger Vehicles (PV) used for commercial purposes, and more recently, passenger vehicles for individual use.
- TIME expects a similar transition in India, with the PV market likely to open up in 2-3 years. The company is currently in discussions with Original Equipment Manufacturers (OEMs) for multiple-sized products tailored to different models, with necessary approvals already in place.
- In FY25, the VAP segment contributed 27% to total revenue, which the company aims to increase to 35% over the next three years (at ~25% CAGR), likely outpacing growth in the Established Products segment (~12% CAGR).
- The rising revenue mix of VAP is expected to bode well for TIME's overall margins.

### Established Products is a low-growth but stable segment

- TIME is a leader in polymer-based industrial packaging in India and ranks among the top three players globally. It is the world's largest manufacturer of large-size plastic drums, with an impressive 50-60% market share in India and a higher share across 10 countries where it is present globally (excluding the US, which is concentrated among three major players).

## Time Technoplast



**Mr. Bharat Vageria, Co-founder, MD & CFO, Time Technoplast Ltd.**

Mr. Vageria is a Fellow of Institute of Chartered Accountants (FCA) and has over three decades of experience in the polymer industry. He, along with three other promoters, founded TIME in 1992. He became the Managing Director in 2022.

**Our initiating coverage report dated 09-06-2025**  
[TIME TECHNOPLAST | Initiate with a BUY: Right Metrics + Right TIME = Rerating in Sight!](#)

- TIME was the first company to launch IBC in India and the third-largest IBC manufacturer worldwide. It is also the second-largest MOX film manufacturer and a major HDPE pipes manufacturer in India.
- TIME caters mainly to companies in the specialty chemicals and non-cyclical sectors (FMCG, F&B, paints). Over time, it has successfully captured a significant share of business from global Fortune 500 companies.
- **The overseas business (34% revenue mix in FY25) has outpaced the domestic business by 1-2% over the past five years and operates at a similar EBITDA margin of 13-14%. It remains resilient to global supply chain disruptions due to local RM sourcing, production, and local selling of products (mainly industrial packaging).**
- **These factors have enabled TIME to grow volumes in the 8-12% range within its Established Products segment (FY25 revenue mix: 73%) while maintaining a ~13% EBITDA margin even amid a volatile business environment.**
- During FY21-25, the segment posted 13.4%/15.2% CAGR in revenue/EBITDA, with EBITDA margin expanding from 12.3% to 13.1%. Going forward, we estimate a 12.3%/14.0% CAGR in revenue/EBITDA, respectively, over FY25-28, with EBITDA margin projected to gradually expand to 13.7% in FY28.

### Certain large opportunities may drive higher capex requirements

- TIME's management anticipates several large opportunities emerging in the next 3-12 months, particularly in products like composite LPG cylinders, fire extinguishers, and hydrogen cylinders.
- The company expects IOCL to float a large tender for 14.5kg composite LPG domestic cylinders shortly, with similar tenders likely to follow from HPCL and BPCL.
- These tenders will require substantial supply volumes of composite LPG cylinders.
- With its current capacity of 1.5m units operating near optimal utilization, TIME will need to undertake additional capex to enhance capacity and meet the anticipated surge in demand.
- Additionally, the company is in discussions with railways to supply composite cylinders for fire extinguishers and with OEMs to supply hydrogen cylinders for drone applications.
- Collectively, these opportunities are expected to drive an additional capex requirement of up to INR5b over the next 1-2 years, over and above the regular annual capex of ~INR1.7b.
- **Accordingly, to fund the additional capex and support its goal of becoming a net-debt-free company by FY27, TIME has secured board approval to raise up to INR10b via QIP route. The approval is valid until Nov'25.**

### Cost reduction measures and recycling of polymers to support profitability

- **To reduce power and fuel costs by over INR250m annually, TIME plans to install solar panels across its manufacturing plants in multiple states.**
- As part of its business restructuring, the company aims to consolidate operationally inefficient small manufacturing units into nearby larger facilities to enhance overall efficiency levels.
- The company is also **exploring options to set up polymer recycling plants across all regions, starting with the west, at a capex of INR1.2b to ensure efficient RM sourcing and compliance with regulatory requirements.**
- TIME has identified assets worth INR1.25b for monetization. Of this, assets worth INR740m have already been monetized over the past two years, with the remainder expected to be monetized in FY26.
- These initiatives are aimed at improving operational efficiency and driving stronger RoCE and cash flows.

### Valuation and view: Maintain robust outlook; BUY

- During FY21-25, TIME recorded a CAGR of 16%/19%/39% in revenue/EBITDA/PAT, with a 14.4% EBITDA margin (up 150bp). We now estimate a CAGR of 15%/16%/23% over FY25-28, with ~15% EBITDA margin.
- Our robust outlook is backed by moderate but stable growth in Established Products (12% revenue CAGR, ~13% EBITDA margin), alongside strong anticipated performance in VAP (20% revenue CAGR, 18%+ EBITDA margin).
- Despite annual capex of ~INR1.7b, **we expect TIME's pre-tax RoCE/RoIC to expand from 18.2% each in FY25 (FY24: 16%-17) to ~23%/26% in FY28 on:** a) healthy operating results, b) better efficiency (sales/gross-block to rise from 1.6x in FY25 to 2.1x in FY28E), and c) tightening of WC cycle (down by 15 days over FY25-28).
- It expects to use an estimated ~INR4b annual operating FCF to pare debt and turn net cash in FY27, from net debt of ~INR6b in FY24 (FY25: INR4.7b).
- **Considering its strong growth prospects, improving return ratios, and attractive valuation (~17x FY27E P/E), we reiterate BUY on TIME with an unchanged TP of INR578, based on 22x FY27E P/E (close to sector average).**


## Story in charts

### Exhibit 1: Bull, Base, and Bear case scenario

	FY25	FY26E	FY27E	FY28E	FY25-28E CAGR
<b>Base case</b> TP: INR 578 (30% upside) (at 22x FY27E P/E)	1. We expect ~15%/16%/23% CAGR in revenue/EBITDA/PAT over FY25-28. 2. Revenue is expected to be driven by ~12% CAGR in Established Products and ~20% CAGR in VAP segments 3. We estimate EBITDA margin of 14.4% in FY25 to gradually improve to 15% in FY28.				
Revenue (INR m)	54,571	62,535	71,636	82,222	14.6
EBITDA (INR m)	7,850	9,139	10,613	12,333	16.3
EBITDA margin	14.4	14.6	14.8	15.0	
PAT (INR m)	3,880	4,860	5,958	7,254	23.2
<b>Bull case</b> TP: INR 800 (80% upside) (at 28x FY27E P/E)	1. We expect ~18%/21%/29% CAGR in revenue/EBITDA/PAT over FY25-28. 2. Revenue is expected to be driven by ~15% CAGR in Established Products and ~24% CAGR in VAP segments 3. We estimate EBITDA margin of 14.4% in FY25 to gradually improve to 15.5% in FY28.				
Revenue (INR m)	54,571	64,211	75,634	89,289	17.8
EBITDA (INR m)	7,850	9,493	11,462	13,853	20.8
EBITDA margin	14.4	14.8	15.2	15.5	
PAT (INR m)	3,880	5,073	6,486	8,227	28.5
<b>Bear case</b> TP: INR 347 (22% downside) (at 16x FY27E P/E)	1. We expect ~9%/8%/13% CAGR in revenue/EBITDA/PAT over FY25-28. 2. Revenue is expected to be driven by ~9% CAGR in Established Products and ~15% CAGR in VAP segments 3. We estimate EBITDA margin of 14.4% in FY25 to decline to <14% in the coming years.				
Revenue (INR m)	54,571	59,466	64,757	70,541	8.9
EBITDA (INR m)	7,850	8,286	8,985	9,742	7.5
EBITDA margin	14.4	13.9	13.9	13.8	
PAT (INR m)	3,880	4,317	4,926	5,588	12.9


Source: Company, MOFSL

### Exhibit 2: Greater focus on VAP (FY25)




Source: Company

### Exhibit 3: Product-wise revenue mix




Source: Company

### Exhibit 4: Balanced geography mix




Source: Company

**Exhibit 5: Revenue CAGR to reach 15%, with EBITDA margin inching up to 15% over FY25-28E**




Source: Company, MOFSL

**Exhibit 6: Higher PAT CAGR of 23% over FY25-28E supported by better margins and lower finance costs from debt reduction**




Source: Company, MOFSL

**Exhibit 7: VAP revenue to outpace Established Products**




Source: Company, MOFSL

**Exhibit 8: Rising VAP share in revenue to drive margins (%)**




Source: Company, MOFSL

**Exhibit 9: Established products – EBITDA, margin trend**




Source: Company, MOFSL

**Exhibit 10: VAPs – EBITDA, margin trend**




Source: Company, MOFSL

**Exhibit 11: Rise in VAP mix (%)**




Source: Company, MOFSL

**Exhibit 12: Reduction in net WC cycle**



Source: Company, MOFSL


**Exhibit 13: Capex trend**



Source: Company, MOFSL


**TO RESULT IN**

**Exhibit 14: Better margins...**




Source: Company, MOFSL

**Exhibit 15: ...strong FCFs, net cash...**




Source: Company, MOFSL

**Exhibit 16: ...improving return ratios**




Source: Company, MOFSL

**Exhibit 17: Revenue/Gross-block trend**



Source: Company, MOFSL

**Exhibit 18: EBITDA/Gross-block trend**



Source: Company, MOFSL

## Financials and valuations

### Consolidated - Income Statement

(INRm)

Y/E March	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E	FY28E
<b>Total Income from Operations</b>	<b>30,049</b>	<b>36,498</b>	<b>42,894</b>	<b>49,925</b>	<b>54,571</b>	<b>62,535</b>	<b>71,636</b>	<b>82,222</b>
Change (%)	-16.0	21.5	17.5	16.4	9.3	14.6	14.6	14.8
RM Cost	21,029	25,771	31,015	35,982	38,860	44,450	50,847	58,292
Employees Cost	1,594	1,826	2,064	2,373	2,652	3,008	3,409	3,872
Other Expenses	3,555	3,843	4,044	4,662	5,209	5,938	6,767	7,725
<b>Total Expenditure</b>	<b>26,178</b>	<b>31,440</b>	<b>37,123</b>	<b>43,017</b>	<b>46,721</b>	<b>53,395</b>	<b>61,023</b>	<b>69,889</b>
% of Sales	87.1	86.1	86.5	86.2	85.6	85.4	85.2	85.0
<b>EBITDA</b>	<b>3,871</b>	<b>5,058</b>	<b>5,771</b>	<b>6,908</b>	<b>7,850</b>	<b>9,139</b>	<b>10,613</b>	<b>12,333</b>
Margin (%)	12.9	13.9	13.5	13.8	14.4	14.6	14.8	15.0
Depreciation	1,510	1,574	1,709	1,726	1,697	1,845	1,934	2,014
<b>EBIT</b>	<b>2,361</b>	<b>3,484</b>	<b>4,062</b>	<b>5,182</b>	<b>6,153</b>	<b>7,294</b>	<b>8,678</b>	<b>10,319</b>
Int. and Finance Charges	977	920	1,052	1,014	915	782	752	740
Other Income	38	30	38	142	53	101	170	267
<b>PBT bef. EO Exp.</b>	<b>1,422</b>	<b>2,594</b>	<b>3,048</b>	<b>4,310</b>	<b>5,290</b>	<b>6,614</b>	<b>8,097</b>	<b>9,845</b>
<b>PBT after EO Exp.</b>	<b>1,422</b>	<b>2,594</b>	<b>3,048</b>	<b>4,310</b>	<b>5,290</b>	<b>6,614</b>	<b>8,097</b>	<b>9,845</b>
Total Tax	364	672	810	1,151	1,346	1,683	2,060	2,505
Tax Rate (%)	25.6	25.9	26.6	26.7	25.4	25.4	25.4	25.4
Minority Interest	24	42	47	55	65	72	79	87
<b>Reported PAT</b>	<b>1,034</b>	<b>1,880</b>	<b>2,190</b>	<b>3,104</b>	<b>3,880</b>	<b>4,860</b>	<b>5,958</b>	<b>7,254</b>
<b>Adjusted PAT</b>	<b>1,034</b>	<b>1,880</b>	<b>2,190</b>	<b>3,104</b>	<b>3,880</b>	<b>4,860</b>	<b>5,958</b>	<b>7,254</b>
Change (%)	-38.8	81.8	16.5	41.7	25.0	25.3	22.6	21.7
Margin (%)	3.4	5.2	5.1	6.2	7.1	7.8	8.3	8.8

### Consolidated - Balance Sheet

(INRm)

Y/E March	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E	FY28E
Equity Share Capital	226	226	226	227	227	227	227	227
Total Reserves	18,802	20,501	22,467	25,301	28,695	32,760	37,698	43,704
<b>Net Worth</b>	<b>19,028</b>	<b>20,727</b>	<b>22,693</b>	<b>25,528</b>	<b>28,921</b>	<b>32,987</b>	<b>37,925</b>	<b>43,931</b>
Minority Interest	483	534	581	635	700	740	780	820
Total Loans	8,097	8,254	8,102	7,446	6,465	5,165	4,765	4,365
Deferred Tax Liabilities	825	902	1,012	1,127	1,331	1,431	1,531	1,631
<b>Capital Employed</b>	<b>28,434</b>	<b>30,417</b>	<b>32,389</b>	<b>34,736</b>	<b>37,418</b>	<b>40,323</b>	<b>45,001</b>	<b>50,747</b>
Gross Block	26,088	27,988	30,389	31,969	33,710	35,460	37,210	38,960
Less: Accum. Deprn.	13,277	14,851	16,561	18,286	19,983	21,828	23,762	25,777
<b>Net Fixed Assets</b>	<b>12,811</b>	<b>13,136</b>	<b>13,828</b>	<b>13,683</b>	<b>13,727</b>	<b>13,633</b>	<b>13,448</b>	<b>13,184</b>
Capital WIP	403	702	676	412	794	694	594	494
<b>Total Investments</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>15</b>	<b>32</b>	<b>32</b>	<b>32</b>	<b>32</b>
<b>Curr. Assets, Loans&amp;Adv.</b>	<b>19,832</b>	<b>22,205</b>	<b>23,789</b>	<b>27,030</b>	<b>29,434</b>	<b>33,263</b>	<b>39,047</b>	<b>46,103</b>
Inventory	7,598	9,077	9,952	10,503	11,483	12,816	14,289	15,950
Account Receivables	7,983	8,669	9,430	10,821	11,624	12,463	13,885	15,486
Cash and Bank Balance	870	941	1,014	1,535	1,779	3,145	5,744	9,248
Loans and Advances	3,381	3,518	3,394	4,171	4,549	4,839	5,129	5,419
<b>Curr. Liability &amp; Prov.</b>	<b>4,610</b>	<b>5,627</b>	<b>5,904</b>	<b>6,404</b>	<b>6,570</b>	<b>7,298</b>	<b>8,121</b>	<b>9,066</b>
Account Payables	3,244	3,849	4,060	4,440	4,511	5,169	5,921	6,796
Other Current Liabilities	1,230	1,631	1,694	1,797	1,877	1,937	1,997	2,057
Provisions	136	147	150	167	182	192	202	212
<b>Net Current Assets</b>	<b>15,221</b>	<b>16,578</b>	<b>17,885</b>	<b>20,626</b>	<b>22,864</b>	<b>25,965</b>	<b>30,926</b>	<b>37,037</b>
Misc Expenditure	0	0	0	0	0	0	0	0
<b>Appl. of Funds</b>	<b>28,434</b>	<b>30,417</b>	<b>32,389</b>	<b>34,736</b>	<b>37,418</b>	<b>40,323</b>	<b>45,001</b>	<b>50,747</b>

E: MOFSL Estimates



## Financials and valuations

### Ratios

Y/E March	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E	FY28E
<b>Basic (INR)</b>								
<b>EPS</b>	<b>4.6</b>	<b>8.3</b>	<b>9.7</b>	<b>13.7</b>	<b>17.1</b>	<b>21.4</b>	<b>26.3</b>	<b>32.0</b>
Cash EPS	11.3	15.3	17.2	21.3	24.6	29.5	34.8	40.8
BV/Share	84.1	91.7	100.3	112.5	127.5	145.4	167.1	193.6
DPS	0.7	1.0	1.3	2.0	2.5	3.5	4.5	5.5
Payout (%)	15.4	12.1	12.9	14.6	14.6	16.3	17.1	17.2
<b>Valuation (x)</b>								
P/E	97.1	53.4	45.8	32.5	26.0	20.7	16.9	13.9
Cash P/E	39.5	29.1	25.7	20.9	18.1	15.0	12.8	10.9
P/BV	5.3	4.8	4.4	3.9	3.5	3.1	2.7	2.3
EV/Sales	3.1	2.6	2.2	1.9	1.8	1.6	1.4	1.3
EV/EBITDA	24.1	18.4	16.2	13.7	12.2	10.8	9.6	8.6
Dividend Yield (%)	0.2	0.2	0.3	0.5	0.6	0.8	1.0	1.2
FCF per share	6.9	4.9	7.1	11.1	12.1	18.1	20.2	24.7
<b>Return Ratios (%)</b>								
RoE	5.6	9.5	10.1	12.9	14.3	15.7	16.8	17.7
RoCE (pre-tax)	9.1	12.5	13.7	16.7	18.2	20.1	21.9	23.3
RoIC (pre-tax)	9.0	12.5	13.7	16.3	18.2	20.5	23.1	25.9
<b>Working Capital Ratios</b>								
Fixed Asset Turnover (x)	1.2	1.3	1.4	1.6	1.6	1.8	1.9	2.1
Asset Turnover (x)	1.1	1.2	1.3	1.4	1.5	1.6	1.6	1.6
Inventory (Days)	92	91	85	77	77	75	73	71
Debtor (Days)	97	87	80	79	78	73	71	69
Creditor (Days)	39	38	35	32	30	30	30	30
<b>Leverage Ratio (x)</b>								
Current Ratio	4.3	3.9	4.0	4.2	4.5	4.6	4.8	5.1
Interest Cover Ratio	2.4	3.8	3.9	5.1	6.7	9.3	11.5	13.9
Net Debt/Equity	0.4	0.4	0.3	0.2	0.2	0.1	0.0	-0.1

### Consolidated - Cash Flow Statement

(INRm)

Y/E March	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E	FY28E
OP/(Loss) before Tax	1,422	2,594	3,048	4,310	5,290	6,614	8,097	9,845
Depreciation	1,510	1,574	1,709	1,726	1,697	1,845	1,934	2,014
Interest & Finance Charges	977	920	1,052	1,014	915	782	752	740
Direct Taxes Paid	-343	-540	-656	-920	-1,209	-1,683	-2,060	-2,505
(Inc)/Dec in WC	-972	-1,682	-1,506	-1,984	-2,451	-1,735	-2,362	-2,607
<b>CF from Operations</b>	<b>2,595</b>	<b>2,866</b>	<b>3,647</b>	<b>4,146</b>	<b>4,243</b>	<b>5,823</b>	<b>6,362</b>	<b>7,488</b>
Others	-25	42	55	-83	62	-61	-130	-227
<b>CF from Operating incl EO</b>	<b>2,570</b>	<b>2,908</b>	<b>3,702</b>	<b>4,063</b>	<b>4,305</b>	<b>5,762</b>	<b>6,231</b>	<b>7,261</b>
(Inc)/Dec in FA	-1,018	-1,803	-2,091	-1,554	-1,557	-1,650	-1,650	-1,650
<b>Free Cash Flow</b>	<b>1,552</b>	<b>1,105</b>	<b>1,612</b>	<b>2,509</b>	<b>2,748</b>	<b>4,112</b>	<b>4,581</b>	<b>5,611</b>
(Pur)/Sale of Investments	0	4	0	-15	-17	0	0	0
Others	-34	6	-65	-301	108	101	170	267
<b>CF from Investments</b>	<b>-1,052</b>	<b>-1,792</b>	<b>-2,155</b>	<b>-1,870</b>	<b>-1,466</b>	<b>-1,549</b>	<b>-1,480</b>	<b>-1,383</b>
Issue of Shares	0	0	0	97	0	0	0	0
Inc/(Dec) in Debt	-308	47	-253	-761	-1,102	-1,300	-400	-400
Interest Paid	-977	-920	-1,052	-1,014	-915	-782	-752	-740
Dividend Paid	-222	-165	-234	-294	-470	-794	-1,021	-1,248
Others	0	0	0	0	0	29	21	13
<b>CF from Fin. Activity</b>	<b>-1,507</b>	<b>-1,038</b>	<b>-1,539</b>	<b>-1,973</b>	<b>-2,487</b>	<b>-2,847</b>	<b>-2,152</b>	<b>-2,374</b>
<b>Inc/Dec of Cash</b>	<b>11</b>	<b>78</b>	<b>8</b>	<b>220</b>	<b>352</b>	<b>1,366</b>	<b>2,600</b>	<b>3,503</b>
Opening Balance	596	607	685	692	912	1,264	2,630	5,230
Other cash & cash equivalent								
<b>Closing Balance</b>	<b>607</b>	<b>685</b>	<b>692</b>	<b>912</b>	<b>1,264</b>	<b>2,630</b>	<b>5,230</b>	<b>8,733</b>

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

---

## NOTES



Explanation of Investment Rating	
Investment Rating	Expected return (over 12-month)
BUY	$\geq 15\%$
SELL	$< -10\%$
NEUTRAL	$< -10\%$ to $15\%$
UNDER REVIEW	Rating may undergo a change
NOT RATED	We have forward looking estimates for the stock but we refrain from assigning recommendation

\*In case the recommendation given by the Research Analyst is inconsistent with the investment rating legend for a continuous period of 30 days, the Research Analyst shall be within following 30 days take appropriate measures to make the recommendation consistent with the investment rating legend.

#### Disclosures

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH000000412. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. MOFSL is a listed public company, the details in respect of which are available on [www.motilaloswal.com](http://www.motilaloswal.com). MOFSL (erstwhile Motilal Oswal Securities Limited - MOSL) is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL), NERL, COMRIS and CCRL and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products. Details of associate entities of Motilal Oswal Financial Services Limited are available on the website at <http://online.reports.motilaloswal.com/Dormant/documents/List%20of%20Associate%20companies.pdf>

MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may; (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the website at <https://galaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx>

A graph of daily closing prices of securities is available at [www.nseindia.com](http://www.nseindia.com), [www.bseindia.com](http://www.bseindia.com). Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to Subject Company for which Research Team have expressed their views.

#### Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

#### For Hong Kong:

This report is distributed in Hong Kong by Motilal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Securities (SEBI Reg. No. INH000000412) has an agreement with Motilal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

#### For U.S.

Motilal Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the "1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act") and together with the 1934 Act, the "Acts", and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement.

The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

#### For Singapore

In Singapore, this report is being distributed by Motilal Oswal Capital Markets (Singapore) Pte. Ltd. ("MOCMSPL") (UEN 201129401Z), which is a holder of a capital markets services license and an exempt financial adviser in Singapore. This report is distributed solely to persons who (a) qualify as "institutional investors" as defined in section 4A(1)(c) of the Securities and Futures Act of Singapore ("SFA") or (b) are considered "accredited investors" as defined in section 2(1) of the Financial Advisers Regulations of Singapore read with section 4A(1)(a) of the SFA. Accordingly, if a recipient is neither an "institutional investor" nor an "accredited investor", they must immediately discontinue any use of this Report and inform MOCMSPL.

In respect of any matter arising from or in connection with the research you could contact the following representatives of MOCMSPL. In case of grievances for any of the services rendered by MOCMSPL write to [grievances@motilaloswal.com](mailto:grievances@motilaloswal.com).

Nainesh Rajani

Email: [nainesh.rajani@motilaloswal.com](mailto:nainesh.rajani@motilaloswal.com)

Contact: (+65) 8328 0276

#### Specific Disclosures

- Research Analyst and/or his/her relatives do not have a financial interest in the subject company(ies), as they do not have equity holdings in the subject company(ies). MOFSL has financial interest in the subject company(ies) at the end of the week immediately preceding the date of publication of the Research Report: Yes.  
Nature of Financial interest is holding equity shares or derivatives of the subject company
- Research Analyst and/or his/her relatives do not have actual/beneficial ownership of 1% or more securities in the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report.  
MOFSL has actual/beneficial ownership of 1% or more securities of the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report: No
- Research Analyst and/or his/her relatives have not received compensation/other benefits from the subject company(ies) in the past 12 months.  
MOFSL may have received compensation from the subject company(ies) in the past 12 months.
- Research Analyst and/or his/her relatives do not have material conflict of interest in the subject company at the time of publication of research report.  
MOFSL does not have material conflict of interest in the subject company at the time of publication of research report.
- Research Analyst has not served as an officer, director or employee of subject company(ies).
- MOFSL has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months.
- MOFSL has not received compensation for investment banking /merchant banking/brokerage services from the subject company(ies) in the past 12 months.

8. MOFSL may have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company(ies) in the past 12 months.
9. MOFSL may have received compensation or other benefits from the subject company(ies) or third party in connection with the research report.
10. MOFSL has not engaged in market making activity for the subject company.

The associates of MOFSL may have:

- financial interest in the subject company
- actual/beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report or date of the public appearance.
- received compensation/other benefits from the subject company in the past 12 months
- any other potential conflict of interests with respect to any recommendation and other related information and opinions; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.
- acted as a manager or co-manager of public offering of securities of the subject company in past 12 months
- be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies)
- received compensation from the subject company in the past 12 months for investment banking / merchant banking / brokerage services or from other than said services.
- Served subject company as its clients during twelve months preceding the date of distribution of the research report.

The associates of MOFSL has not received any compensation or other benefits from third party in connection with the research report

Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, It does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures.

#### Analyst Certification

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

#### Terms & Conditions:

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

#### Disclaimer:

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alternations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, not its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays.

This report is meant for the clients of Motilal Oswal only.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022 - 71934200 / 71934263;

www.motilaloswal.com. Correspondence Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad (West), Mumbai- 400 064. Tel No: 022 71881000. Details of Compliance Officer: Neeraj Agarwal, Email Id: na@motilaloswal.com, Contact No.:022-40548085.

Grievance Redressal Cell:

Contact Person	Contact No.	Email ID
Ms. Hemangi Date	022 40548000 / 022 67490600	query@motilaloswal.com
Ms. Kumud Upadhyay	022 40548082	servicehead@motilaloswal.com
Mr. Ajay Menon	022 40548083	am@motilaloswal.com

Registration details of group entities.: Motilal Oswal Financial Services Ltd. (MOFSL): INZ000158836 (BSE/NSE/MCX/NCDEX); CDSL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412 . AMFI: ARN : 146822. IRDA Corporate Agent – CA0579. Motilal Oswal Financial Services Ltd. is a distributor of Mutual Funds, PMS, Fixed Deposit, Insurance, Bond, NCDs and IPO products.

Customer having any query/feedback/ clarification may write to query@motilaloswal.com. In case of grievances for any of the services rendered by Motilal Oswal Financial Services Limited (MOFSL) write to grievances@motilaloswal.com, for DP to dp@motilaloswal.com.